All In Biotech

Drug Trial Radar · NCT05385783

A Study of a Psilocybin Analog (CYB003) in Healthy Participants With and Without Major Depressive Disorder

A Phase I/IIa, Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label Relative Bioavailability and Food Effect Cohort to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Oral Doses of CYB003 in Healthy Participants With and Without Major Depressive Disorder (MDD)

Last checked: Nov 19, 2026Latest source record: Mar 25, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

57

Actual

Start

Aug 2, 2022

Primary completion

Oct 16, 2023

Study completion Jan 18, 2024

Sponsor

Lead sponsor
Cybin IRL LimitedIndustry
Sponsor type
Industry
Collaborators
Clinilabs Drug Development Corporation; Drug Safety Navigator
First posted
May 23, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 21 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine the safety and tolerability of ascending oral doses of CYB003 in healthy participants with and without major depressive disorder (MDD).

Conditions

  • Major Depressive Disorder

Interventions

  • CYB003Drug

    CYB003 is a synthetic psilocybin analog.

  • PsychotherapyBehavioral

    Manualized psychotherapy (called EMBARK) performed by facilitators

  • PlaceboDrug

    Placebo

  • Psychological SupportBehavioral

    Manualized psychological support performed by facilitators

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse Events (All Arms)Time frame: Day 1 thru End of Study Visit (which is: Day 56 Arms A & B; Day 28 Arms C & D; Day 35 Arms E)
  2. Resting 12 Lead ECG ventricular rate (Arms A & B)Time frame: Screening, Day -1, Day 1, Day 2, Day 21, Day 22, & Day 23
  3. Resting 12 Lead ECG ventricular rate (Arms C & D)Time frame: Screening, Day -1, Day 1, Day 2, Day 7, Day 8, & Day 9
  4. Resting 12 Lead ECG ventricular rate (Arms E)Time frame: Screening, Day -1, Day1, Day 2, Day 7, Day 8, Day 9, Day 14, Day 15, Day 16
  5. Resting 12 Lead ECG PR interval (Arms A & B)Time frame: Screening, Day -1, Day 1, Day 2, Day 21, Day 22, Day 23
  6. Resting 12 Lead ECG PR interval (Arms C & D)Time frame: Screening, Day -1, Day 1, Day 2, Day 7, Day 8, & Day 9
  7. Resting 12 Lead ECG PR interval (Arms E)Time frame: Screening, Day -1, Day1, Day 2, Day 7, Day 8, Day 9, Day 14, Day 15, Day 16
  8. Resting 12 Lead ECG QRS duration (Arms A & B)Time frame: Screening, Day -1, Day 1, Day 2, Day 21, Day 22, Day 23
  9. Resting 12 Lead ECG QRS duration (Arms C & D)Time frame: Screening, Day -1, Day 1, Day 2, Day 7, Day 8, & Day 9
  10. Resting 12 Lead ECG QRS duration (Arms E)Time frame: Screening, Day -1, Day1, Day 2, Day 7, Day 8, Day 9, Day 14, Day 15, Day 16
  11. Resting 12 Lead ECG QT interval (Arms A & B)Time frame: Screening, Day -1, Day 1, Day 2, Day 21, Day 22, Day 23
  12. Resting 12 Lead ECG QT interval (Arms C & D)Time frame: Screening, Day -1, Day 1, Day 2, Day 7, Day 8, & Day 9
  13. Resting 12 Lead ECG QT interval (Arms E)Time frame: Screening, Day -1, Day1, Day 2, Day 7, Day 8, Day 9, Day 14, Day 15, Day 16
  14. Resting 12 Lead ECG QTcF (Arms A & B)Time frame: Screening, Day -1, Day 1, Day 2, Day 21, Day 22, Day 23
  15. Resting 12 Lead ECG QTcF (Arms C & D)Time frame: Screening, Day -1, Day 1, Day 2, Day 7, Day 8, & Day 9
  16. Resting 12 Lead ECG QTcF (Arms E)Time frame: Screening, Day -1, Day1, Day 2, Day 7, Day 8, Day 9, Day 14, Day 15, Day 16
  17. Holter monitoring (Arms A & B)Time frame: Day -1, Day 1, Day 22
  18. Holter monitoring (Arms C & D)Time frame: Day -1, Day 1, Day 8
  19. Holter monitoring (Arm E)Time frame: Day -1, Day 1, Day 8, Day 15
  20. Columbia Suicide Severity Rating Scale (CSSRS) Lifetime version (All Arms)Time frame: Screening
  21. Columbia Suicide Severity Rating Scale (CSSRS) Since Last Visit (SLV) (Arms A & B)Time frame: Day -1, Day 2, Day 10, Day 17, Day 21, Day 23, Day 31, Day 38, Day 42, and Day 56
  22. Columbia Suicide Severity Rating Scale (CSSRS) Since Last Visit (SLV) (Arms C & D)Time frame: Day -1, Day 2, Day 7, Day 9, Day 15, Day 21, Day 28
  23. Columbia Suicide Severity Rating Scale (CSSRS) Since Last Visit (SLV) (Arm E)Time frame: Day -1, Day 2, Day 7, Day 9, Day 14, Day 16, Day 21, Day 28, Day 35

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • CenExel ACMR

    Atlanta, Georgia

  • iResearch Atlanta

    Decatur, Georgia

  • Clinilabs Drug Development Corporation

    Eatontown, New Jersey

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.